FLT3 antibody-based therapeutics for leukemia therapy

International Journal of Hematology

Volumn 82, Issue 2, 2005, Pages 108-114

  Li, Yiwen ^a   Zhu, Zhenping ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Acute myeloid leukemia; FLT3; Immunoconjugate; Monoclonal antibody; Receptor tyrosine kinase; Small molecule inhibitor; Targeted therapy

Indexed keywords

ANTIBODY CONJUGATE; BEVACIZUMAB; CETUXIMAB; D4 3; ERLOTINIB; FLT3 LIGAND; GEFITINIB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; IMC EB10; IMC NC7; INDOLE DERIVATIVE; MIDOSTAURIN; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SU 5614; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; DOSE RESPONSE; DRUG MECHANISM; HUMAN; LEUKEMIA; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMMUNOCONJUGATES; LEUKEMIA; MICE; MICE, INBRED NOD; MICE, SCID;

EID: 24144454174     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05068     Document Type: Review

References (60)

1. Ehrlich P. On immunity with special reference to cell life. Proc R Soc London. 1900;66:424-448.
2. Kohler G, Milstein C Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-497.
3. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Scad Sci USA. 1984; 81:6851-6855.
4. Jones PT, Dear PH, Foote J, Newberger MS, Winter G. Replacing the complementarity determining regions in a human antibody with those from a mouse. Nature. 1986;321:522-525.
5. Jakobovits A. Production and selection of antigen-specific fully human monoclonal antibodies from mice engineered with human Ig loci. Adv Drug Deliv Rev. 1998;31:33-42.
6. de Haard HJ, van Neer N, Reurs A, et al. A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. J Biol Chem. 1999;274: 18218-18230.
7. Glennie MJ, Johnson WM. Clinical trials of antibody therapy. Immunol Today. 2000;21:403-410.
8. Little M, Kipriyanov SM, Gall FL, Moldenhauer G. Of mice and men: hybridoma and recombinant antibodies. Immunol Today. 2000;21:364-370.
9. Trill JJ, Shatzman AR, Ganguly S. Production of monoclonal antibodies in COS and CHO cells. Curr Opin Biotechnol. 1995;6: 553-560.
10. Rosnet O, Schiff C, Pebusque MJ, et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood. 1993; 82:1110-1119.
11. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity. 1995;3:147-161.
12. + lympho-myeloid stem cells lacking erythro-megakaryocytic potential: a revised road map for adult blood lineage commitment. Cell. 2005;121:295-306.
13. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100:1532-1542.
14. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10: 1911-1918.
15. Yamamoto Y, Kiyoi H, Nakano Y, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 2001;97:2434-2439.
16. Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies. Blood. 2005;105:22-30.
17. Levis M, Small D. Small molecule FLT3 tyrosine kinase inhibitors. Curr Pharm Des. 2004;10:1183-1193.
18. Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002;99:3885-3891.
19. Kelly LM, Yu JC, Boulton CL, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 2002;1:421-432.
20. Yee KWH, O'Farrell AM, Smolich BD, et al. SU5416 and SU5614 inhibit wild-type and activated mutant FLT3 signaling in leukemia cells. Blood. 2002;100:2941-2949.
21. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1:433-443.
22. Hofmann WK, Komor M, Hoelzer D, Ottmann OG. Mechanisms of resistance to STI571 (imatinib) in Philadelphia-chromosome positive acute lymphoblastic leukemia. Leuk Lymphoma. 2004;45: 655-660.
23. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2005;105:986-993.
24. Fiedler W, Mesters R, Tinnefeid H, et al. A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 2003;102:2763-2767.
25. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103: 3669-3676.
26. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105:54-60.
27. Cools J, Mentens N, Furet P, et al. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. Cancer Res. 2004;64:6385-6389.
28. Bagrintseva K, Schwab R, Kohl TM, et al. Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells. Blood. 2004;103:2266-2275.
29. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3:391-400.
30. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7:301-311.
31. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
32. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
33. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
34. Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol. 2002;29:36-40.
35. Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother. 1993;37:255-263.
36. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
37. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443-446.
38. Sievers EL, Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol. 2001;13:522-527.
39. Krasner C, Joyce RM. Zevalin: 90yttrium labeled anti-CD20 (ibritumomab tiuxetan), a new treatment for non-Hodgkin's lymphoma. Curr Pharm Biotechnol. 2001;2:341-349.
40. Cheson B. Bexxar (Corixa/GlaxoSmithKline). Curr Opin Investig Drugs. 2002;3:165-170.
41. Cao Y, Lam L. Bispecific antibody conjugates in therapeutics. Adv Drug Deliv Rev. 2003;55:171-197.
42. Kipriyanov SM, Le Gall F. Recent advances in the generation of bispecific antibodies for tumor immunotherapy. Curr Opin Drug Discov Devel. 2004;7:233-242.
43. Withoff S, Helfrich W, de Leij LF, Molema G. Bi-specific antibody therapy for the treatment of cancer. Curr Opin Mol Ther. 2001;3:53-62.
44. van Ojik HH, Valerius T. Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy. Crit Rev Oncol Hematol. 2001;38:47-61.
45. Chang CH, Sharkey RM, Rossi EA, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther. 2002;1:553-563.
46. Ford CH, Osborne PA, Rego BG, Mathew A. Bispecific antibody targeting of doxorubicin to carcinoembryonic antigen-expressing colon cancer cell lines in vitro and in vivo. Int J Cancer. 2001;92: 851-855.
47. DeFreitas E, Suzuki H, Herlyn D, et al. Human antibody induction to the idiotypic and anti-idiotypic determinants of a monoclonal antibody against a gastrointestinal carcinoma antigen. Curr Top Microbiol Immunol. 1985;119:75-89.
48. Wentworth AD, Jones LH, Wentworth P Jr, Janda KD, Lerner RA. Antibodies have the intrinsic capacity to destroy antigens. Proc Natl Acad Sci USA. 2000;91:10930-10935.
49. French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med. 1999;5:548-553.
50. Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000;60:2444-2448.
51. Li Y, Li H, Wang MN, et al. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody. Blood. 2004;104:1137-1144.
52. Piloto O, Levis M, Huso D, et al. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 2005;65:1514-1522.
53. Willams B, Atkins A, Zhang H, et al. Cell-based selection of internalizing antagonistic fully human antibodies directed against FLT3 for suppression of leukemia cell growth. Leukemia. 2005. In press.
54. Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene. 2002;21:2555-2563.
55. Griffith J, Black J, Faerman C, et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell. 2004;13: 169-178.
56. Zheng R, Levis M, Piloto O, et al. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 2004;103:267-274.
57. Payne G. Progress in immunoconjugate cancer therapeutics. Cancer Cell. 2003;3:207-212.
58. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2001;1:118-129.
59. Li Y, Li H, Wang MN, et al. Suppression of leukemia growth by a novel anti-FLT3 antibody-auristatin conjugate [abstract]. Proc Am Assoc Cancer Res 96th Annu Meeting. 2005;46. Abstract 6181.
60. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol. 2003;21:778-784.